antibodies invivo mab anti mouse pd 1 (Bio X Cell)
Bio X Cell is a verified supplier 
Bio X Cell manufactures this product 
96
Structured Review
Bio X Cell
antibodies invivo mab anti mouse pd 1
Antibodies Invivo Mab Anti Mouse Pd 1, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 96/100, based on 204 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+mouse+pd+1+mab/Anti-Proximal+Nephrogenic+Antigen+(Renal+Cell+Marker)+Monoclonal+Antibody/bio_rxiv__64898__2026__03__17__712479-219-0-20
Average 96 stars, based on 204 article reviews
Antibodies Invivo Mab Anti Mouse Pd 1, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 96/100, based on 204 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+mouse+pd+1+mab/Anti-Proximal+Nephrogenic+Antigen+(Renal+Cell+Marker)+Monoclonal+Antibody/bio_rxiv__64898__2026__03__17__712479-219-0-20
Average 96 stars, based on 204 article reviews
antibodies invivo mab anti mouse pd 1 - by Bioz Stars,
2026-09
96/100 stars
Images
1) Product Images from "Arginine synthesis pathway and ASS1 play a critical role in mRNA translation reprogramming and ICI resistance in cutaneous melanoma"
Article Title: Arginine synthesis pathway and ASS1 play a critical role in mRNA translation reprogramming and ICI resistance in cutaneous melanoma
Journal: bioRxiv
doi: 10.64898/2026.03.17.712479
Figure Legend Snippet: A , C57/BL6 mice were inoculated with murine Braf V600E Pten -/- melanoma cells (YUMM1.1), expressing a shRNA targeting ASS1 or a shRNA control. When tumors reached a mean of 100mm3, mice were treated with anti-PD-1 (4mg/kg-1) or isotype IgG control. The data are presented as the mean ± SEM for each group (n=10 mice per group). p-values were calculated using two-way ANOVA. B , Percentage of CD45-positive cells in tumors was determined by flow cytometry in tumors presented in B. The data are presented as the mean ± SEM (YUMM1.1shCTL n=9 tumors ; YUMM1.1shASS1 n=10 tumors). C , Deconvolution performed using CIBERSORTx performed on tumors from the experiment presented in A. D , Ratio CD8+ cells to malignant cells (Mal.) from the panel C is presented in tumor from the experiment presented in the panel A. E , Representative immunostaining of CD8+ T lymphocytes (red, CD8a) and nuclei (blue, DAPI) on frozen tumor sections of mice from panel A. F, Representation of CD8+ cells shown in D, the data are presented as the mean ± SEM (n=9 tumors). G. Representative immunostaining of CD8+ T cells and granzyme B on frozen tumor sections of mice from panel A.
Techniques Used: Expressing, shRNA, Control, Flow Cytometry, Immunostaining
![A , Immunoblot showing the expression levels of indicated protein in ICI-resistant YUMM1.1 cell line after 3 days of treatment with MDLA. HSP90 serves as a loading control. B , ASS1 enzymatic activity was performed in ICI-resistant YUMM1.1 cell line after 3 days of treatment with (n=3; mean ± SEM). C , Intracellular concentration of arginine was measure in ICI-resistant YUMM1.1 cells after 3 days of treatment with MDLA. (n=3; mean ± SEM). D. Schematic representation of the impact of arginine on the control upstream of mTORC1. E. Immunoprecipaption was performed on WM9 cells transfected with HA-tagged CASTOR1 and cultured for 3 days in the presence of different concentration of arginine and MDLA. Immunoblot showing the expression levels of indicated protein. F , Immunoblot showing the expression levels of indicated protein in ICI-resistant YUMM1.1 cell line. β-actine was use as a loading control. G , Immunoblot showing the expression levels of indicated protein in WM9 melanoma cell line. H , Renilla over Firefly luminescent ratio quantification in ICI-resistant YUMM1.1 cell line. I , Renilla over Firefly luminescent ratio quantification in WM9 melanoma cell line. J , YUMM1.1 cells treated or not with MDLA were then pulsed for 30 min with [ 35 S]Cys/Met, and the incorporation of 35 S into proteins was quantified and normalized to the total protein amount. Cells treated 30 minutes with 100µg/mL of cycloheximide (CHX) are used as a positive control. The data are presented as the mean (n = 3). K , WM9 cells treated or not with MDLA were then pulsed for 30 min with [ 35 S]Cys/Met, and the incorporation of 35 S into proteins was quantified and normalized to the total protein amount. Cells treated 30 minutes with 100µg/mL of cycloheximide (CHX) are used as a positive control. The data are presented as the mean (n = 3). L , Immunoblot showing the expression levels of indicated protein in cells from tumors of patients with metastatic melanoma. HSP90 serves as a loading control. M , Renilla over Firefly luminescent ratio quantification in cells from tumors of patients with metastatic melanoma (n=3; mean ± SEM). N , Cells isolated from tumors of patients with metastatic melanoma were treated or not with MDLA were then pulsed for 30 min with [ 35 S]Cys/Met, and the incorporation of 35 S into proteins was quantified and normalized to the total protein amount. Cells treated 30 minutes with 100µg/mL of cycloheximide (CHX) are used as a positive control. The data are presented as the mean (n = 3). O , C57BL/6 mice were inoculated with murine Braf V600E Pten -/- melanoma cells (YUMM1.1). When tumors reached a mean of 100mm 3 , mice were treated with MDLA (700mg.kg-1) or PBS, twice a day. Two days after the beginning of the MDLA treatment, mice were treated with anti-PD-1 (4mg/kg-1) or isotype IgG control, once per day, every two days, 3 times. Mice were treated with an additional dose of anti-PD-1 or isotype IgG control at day 24. Tumor growth was monitored for 27 days. The data representing the tumor growth are presented as the mean ± SEM for each group (n=10 mice per group). p -values were calculated using two-way ANOVA. P , Percentage of CD45-positive cells in tumors was determined by flow cytometry in tumors presented in P. The data are presented as a ratio of percentage between CD45-positive cells versus CD45-negative cells. (n=10 tumors per group, mean ± SEM). Q , Percentage of CD45 and CD8a-double positive cells in tumors, determined by flow cytometry in tumors presented in P. (n=10 tumors per group, mean ± SEM).](https://bio-rxiv-images-cdn.bioz.com/dois_ending_with_79/10__64898_slash_2026__03__17__712479/10__64898_slash_2026__03__17__712479___F6.large.jpg "... of the MDLA treatment, mice were treated with anti-PD-1 (4mg/kg-1) or isotype IgG control, once per day, ...")
Figure Legend Snippet: A , Immunoblot showing the expression levels of indicated protein in ICI-resistant YUMM1.1 cell line after 3 days of treatment with MDLA. HSP90 serves as a loading control. B , ASS1 enzymatic activity was performed in ICI-resistant YUMM1.1 cell line after 3 days of treatment with (n=3; mean ± SEM). C , Intracellular concentration of arginine was measure in ICI-resistant YUMM1.1 cells after 3 days of treatment with MDLA. (n=3; mean ± SEM). D. Schematic representation of the impact of arginine on the control upstream of mTORC1. E. Immunoprecipaption was performed on WM9 cells transfected with HA-tagged CASTOR1 and cultured for 3 days in the presence of different concentration of arginine and MDLA. Immunoblot showing the expression levels of indicated protein. F , Immunoblot showing the expression levels of indicated protein in ICI-resistant YUMM1.1 cell line. β-actine was use as a loading control. G , Immunoblot showing the expression levels of indicated protein in WM9 melanoma cell line. H , Renilla over Firefly luminescent ratio quantification in ICI-resistant YUMM1.1 cell line. I , Renilla over Firefly luminescent ratio quantification in WM9 melanoma cell line. J , YUMM1.1 cells treated or not with MDLA were then pulsed for 30 min with [ 35 S]Cys/Met, and the incorporation of 35 S into proteins was quantified and normalized to the total protein amount. Cells treated 30 minutes with 100µg/mL of cycloheximide (CHX) are used as a positive control. The data are presented as the mean (n = 3). K , WM9 cells treated or not with MDLA were then pulsed for 30 min with [ 35 S]Cys/Met, and the incorporation of 35 S into proteins was quantified and normalized to the total protein amount. Cells treated 30 minutes with 100µg/mL of cycloheximide (CHX) are used as a positive control. The data are presented as the mean (n = 3). L , Immunoblot showing the expression levels of indicated protein in cells from tumors of patients with metastatic melanoma. HSP90 serves as a loading control. M , Renilla over Firefly luminescent ratio quantification in cells from tumors of patients with metastatic melanoma (n=3; mean ± SEM). N , Cells isolated from tumors of patients with metastatic melanoma were treated or not with MDLA were then pulsed for 30 min with [ 35 S]Cys/Met, and the incorporation of 35 S into proteins was quantified and normalized to the total protein amount. Cells treated 30 minutes with 100µg/mL of cycloheximide (CHX) are used as a positive control. The data are presented as the mean (n = 3). O , C57BL/6 mice were inoculated with murine Braf V600E Pten -/- melanoma cells (YUMM1.1). When tumors reached a mean of 100mm 3 , mice were treated with MDLA (700mg.kg-1) or PBS, twice a day. Two days after the beginning of the MDLA treatment, mice were treated with anti-PD-1 (4mg/kg-1) or isotype IgG control, once per day, every two days, 3 times. Mice were treated with an additional dose of anti-PD-1 or isotype IgG control at day 24. Tumor growth was monitored for 27 days. The data representing the tumor growth are presented as the mean ± SEM for each group (n=10 mice per group). p -values were calculated using two-way ANOVA. P , Percentage of CD45-positive cells in tumors was determined by flow cytometry in tumors presented in P. The data are presented as a ratio of percentage between CD45-positive cells versus CD45-negative cells. (n=10 tumors per group, mean ± SEM). Q , Percentage of CD45 and CD8a-double positive cells in tumors, determined by flow cytometry in tumors presented in P. (n=10 tumors per group, mean ± SEM).
Techniques Used: Western Blot, Expressing, Control, Activity Assay, Concentration Assay, Transfection, Cell Culture, Positive Control, Isolation, Flow Cytometry
Related Articles
Control:Article Title: A novel ROR1-targeting antibody-PROTAC conjugate promotes BRD4 degradation for solid tumor treatment. Article Snippet: .. When the tumors reached a volume of 50-100 mm3, the mice were treated intravenously with PBS, ROR1 mAb (15 mg/kg), Isotype DAC control (15 mg/kg), ROR1 DAC (15 mg/kg), MZ1 (5 mg/kg), Injection:Article Title: Histone lactylation-driven feedback loop modulates cholesterol-linked immunosuppression in pancreatic cancer Article Snippet: .. In further studies, Panc02-OVA and KPC-OVA tumor-bearing C57BL/6J mice were given intraperitoneally either 100 μg of Article Title: Intestinal fungal signatures and their impact on immune checkpoint inhibitor efficacy: a multi-cohort meta-analysis Article Snippet: .. One week after tumor inoculation, each mouse was intraperitoneally injected with 200 μg of Article Title: Anti-PD-1 exacerbates bleomycin-induced lung injury in mice via Caspase-3/GSDME-mediated pyroptosis Article Snippet: The BLM group was subjected to a single intratracheal instillation of bleomycin (3 mg/mL; Nippon Kayaku, Japan) at 2 mg/kg (Supplementary Fig. ). .. In the BLM+aPD-1 group, the mice received both a single intratracheal instillation of bleomycin and an intraperitoneal injection of an Article Title: Anti-PD-1 exacerbates bleomycin-induced lung injury in mice via Caspase-3/GSDME-mediated pyroptosis Article Snippet: The BLM group was subjected to a single intratracheal instillation of bleomycin (3 mg/mL; Nippon Kayaku, Japan) at 2 mg/kg (Supplementary Fig. S1A). .. In the BLM+aPD-1 group, the mice received both a single intratracheal instillation of bleomycin and an intraperitoneal injection of an Article Title: RNF2 induces myeloid-derived suppressor cells chemotaxis and promotes hepatocellular carcinoma progression through the TRAF2-NF-κB signaling axis Article Snippet: .. Mice were treated weekly with 200 μg of other:Article Title: Cordyceps sinensis enhances the efficacy of anti-PD-1 immunotherapy in Lewis lung adenocarcinoma. Article Snippet: The Mouse Assay:Article Title: RNF2 induces myeloid-derived suppressor cells chemotaxis and promotes hepatocellular carcinoma progression through the TRAF2-NF-κB signaling axis Article Snippet: .. Mice were treated weekly with 200 μg of |
